317 related articles for article (PubMed ID: 32581551)
1. Silencing
Liu C; He S; Zhang J; Li S; Chen J; Han C
Onco Targets Ther; 2020; 13():4905-4915. PubMed ID: 32581551
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis.
Tang F; Li S; Liu D; Chen J; Han C
Transl Cancer Res; 2020 Mar; 9(3):1584-1593. PubMed ID: 35117506
[TBL] [Abstract][Full Text] [Related]
3. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
Cui H; Wang Q; Miller DD; Li W
Front Pharmacol; 2021; 12():637098. PubMed ID: 33841154
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
5. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
Zhao B; Cheng X; Zhou X
Melanoma Res; 2018 Dec; 28(6):521-526. PubMed ID: 30192303
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
7. Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis
Wang L; Otkur W; Wang A; Wang W; Lyu Y; Fang L; Shan X; Song M; Feng Y; Zhao Y; Piao HL; Qi H; Liu JW
Front Pharmacol; 2022; 13():906043. PubMed ID: 36034784
[TBL] [Abstract][Full Text] [Related]
8. Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway.
Chiu YJ; Yang JS; Tsai FJ; Chiu HY; Juan YN; Lo YH; Chiang JH
Environ Toxicol; 2022 Apr; 37(4):868-879. PubMed ID: 34994998
[TBL] [Abstract][Full Text] [Related]
9. The positive correlation between drug addiction and drug dosage in vemurafenib-resistant melanoma cells is underpinned by activation of ERK1/2-FRA-1 pathway.
Rao M; Shi B; Yuan Y; Wang Y; Chen Y; Liu X; Li X; Zhang M; Liu X; Sun X
Anticancer Drugs; 2020 Nov; 31(10):1026-1037. PubMed ID: 32868647
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin exerts an antitumor effect in vemurafenib-resistant melanoma cells.
Nishiya M; Yasuhira S; Shibazaki M; Oikawa H; Masuda T; Maesawa C
Anticancer Drugs; 2019 Jun; 30(5):451-457. PubMed ID: 30920401
[TBL] [Abstract][Full Text] [Related]
11. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
12. ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Peng U; Wang Z; Pei S; Ou Y; Hu P; Liu W; Song J
Oncol Rep; 2017 Feb; 37(2):1270-1276. PubMed ID: 28035401
[TBL] [Abstract][Full Text] [Related]
13. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
14. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
16. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
[TBL] [Abstract][Full Text] [Related]
17. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
18. The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B.
Jiang SL; Wang ZB; Zhu T; Jiang T; Fei JF; Liu C; Luo C; Cheng Y; Liu ZQ
Front Pharmacol; 2021; 12():720619. PubMed ID: 34512348
[TBL] [Abstract][Full Text] [Related]
19. Targeting CDC7 sensitizes resistance melanoma cells to BRAF
Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY
Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy
Li H; Wang Y; Su R; Jia Y; Lai X; Su H; Fan Y; Wang Y; Xing W; Qin J
Front Oncol; 2022; 12():794216. PubMed ID: 35141161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
